Search
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalIt is active against Gram-positive and Gram-negative bacteria. … In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI).
Synonyms: (4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidCategories: Heterocyclic Compounds, 2-RingFosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalFosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. … It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 SubstratesProducts: BRIAN EX, FOSEMRED 150 MG/VIALChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsProducts: Truxal 50 mg - Filmtabletten, CHLORPROTHIXEN-NEURAX 100Tigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalIt was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. … Food and Drug Administration (FDA) on June 17, 2005.
Synonyms: (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamideProducts: TİGENEX 50 MG İNFÜZYONLUK ÇÖZELTİ İÇİN TOZ, 10 FLAKON, TYGEPOL 50 MG I.V. İNFÜZYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ, 10 ADETClofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawn[A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis … It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP3A InhibitorsProducts: CLOFZIMIN® 100 MG, Fazim 50 mg CapsuleLoxapine
go.drugbank.com/drugs/DB00408ApprovedInvestigationalAn antipsychotic agent used in schizophrenia. [PubChem]
Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsSynonyms: 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepineRiluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalA glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingProducts: RILUZOL - CT 50 MG, TEGLUTIK 5 MG/ ML ORAL SÜSPANSIYON, 300 MLTucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.
Categories: MATE 2 Inhibitors, Heterocyclic Compounds, 2-RingProducts: TUKYSA 150 mg film-coated tablets, TUKYSA (TUCATINIB) FILM-COATED TABLETS 150 mgUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigational[A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. … Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
Categories: Interleukin-23 AntagonistProducts: STELARA 130 MG / 26 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, STELARA 130 MGGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalIL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357]. … Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23.
Categories: Interleukin-23 Antagonist, Interleukin-23 Subunit p19Products: TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET